Shaun deLacy is an associate in the firm’s IP Litigation group. He joined Goodwin in 2014. 

Mr. deLacy focuses his practice on patent matters, particularly biotechnology and pharmaceuticals. Mr. deLacy’s experience includes representation of clients in a variety of Hatch-Waxman matters relating to various pharmaceutical products. Mr. deLacy has significant trial experience before federal district courts, including in both bench and jury trials. Mr. deLacy also has significant experience with inter partes reviews before the Patent Trials and Appeal Board.  

In addition to his work for clients, Mr. deLacy also contributes thought leadership on software patentability issues and is an editor for Goodwin’s Big Molecule Watch blog covering news and providing analysis in the biosimilar field.

Areas of Practice
Domaines D’Expertise
Scientific Experience





Representative matters include:

  • Defending IBM as a third-party intervenor in patent infringement suits before the United States Court of Federal Claims against the federal government, regarding computer systems for providing disaster warnings.
  • Represented AMAG Pharmaceuticals, Inc. in a patent infringement litigation filed by AMAG against Sandoz Inc. regarding Sandoz’s application to market a generic version of AMAG’s IV iron supplement, Feraheme® (ferumoxytol).
  • Represented Teva Pharmaceuticals USA, Inc. in a patent infringement litigation, including a jury trial, filed by GlaxoSmithKline regarding Teva’s marketing of a generic version of GSK’s heart failure treatment Coreg® (carvedilol).
  • Represented Lupin Ltd. in a patent infringement litigation, including a trial, filed by Senju Pharaceutical Co. and Bausch & Lomb, Inc. regarding Lupin’s application to market a generic version of Senju’s anti-inflammatory ophthalmic solution Prolensa® (bromfenac ophthalmic solution).
  • Represented Actavis Laboraties FL, Inc. in a patent infringement litigation, including a trial and successful appeal, filed by Bayer Pharma AG regarding Actavis’s application to market a generic version of Bayer’s erectile dysfunction treatment Staxyn® (vardenafil orally dissolving tablet).
  • Represented Glenmark Pharmaceuticals in patent infringement litigation, including trial and appeal to the Federal Circuit, filed by Intendis GmbH and Bayer Healthcare Pharmaceuticals, Inc. regarding Glenmark’s application to market a generic version of Bayer’s topical rosacea treatment, Finacea® (azelaic acid).
Professional Experience

Prior to attending law school, Mr. deLacy was a science teacher at Bronx High School of Science, where he taught physics, chemistry and electrical engineering classes for over 120 students from grades 10 - 12.

During his time at Fordham University School of Law, Mr. deLacy participated in the Samuelson-Glushko Intellectual Property and Information Law clinic where he served primarily indigent clients regarding their intellectual property matters. At the clinic, Mr. deLacy authored a utility patent application for a mechanical technology and advised other clients on the prosecution of their existing applications and on the patentability of their inventions.

Mr. deLacy has assisted clients in pro bono matters, including representation of minors in immigration case and environmental conservation groups in actions brought under the Endangered Species Act.






J.D., 2014
Fordham University School of Law
B.S., Applied Physics, 2008
Columbia University, Fu Foundation School of Engineering and Applied Science



New York
New Jersey
Get In Touch
German Translation
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique